Omeros Stock Hits Five-Year High On Blowout Quarter

Omeros (OMER) stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant complications. The biotech company won approval for Yartemlea in December. It’s the only treatment approved for patients with thrombotic microangiopathy due to a stem cell transplant. In this condition, small blood clots form in blood vessels throughout the body. In its…